Muscle mass and association to quality of life in non-small cell lung cancer patients

Asta Bye, Bjørg Sjøblom, Tore Wentzel-Larsen, Bjørn H Grønberg, Vickie E Baracos, Marianne J Hjermstad, Nina Aass, Roy M Bremnes, Øystein Fløtten, Marit Jordhøy, Asta Bye, Bjørg Sjøblom, Tore Wentzel-Larsen, Bjørn H Grønberg, Vickie E Baracos, Marianne J Hjermstad, Nina Aass, Roy M Bremnes, Øystein Fløtten, Marit Jordhøy

Abstract

Background: Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected QoL outcomes in advanced non-small cell lung cancer (NSCLC) at diagnosis.

Methods: Baseline data from patients with stage IIIB/IV NSCLC and performance status 0-2 enrolled in three randomized trials of first-line chemotherapy (n = 1305) were analysed. Associations between SMI (cm2 /m2 ) and SMD (Hounsfield units) based on computed tomography-images at the third lumbar level and self-reported physical function (PF), role function (RF), global QoL, fatigue, and dyspnoea were investigated by linear regression using flexible non-linear modelling.

Results: Complete data were available for 734 patients, mean age 65 years. Mean SMI was 47.7 cm2 /m2 in men (n = 420) and 39.6 cm2 /m2 in women (n = 314). Low SMI values were non-linearly associated with low PF and RF (men P = 0.016/0.020, women P = 0.004/0.012) and with low global QoL (P = 0.001) in men. Low SMI was significantly associated with high fatigue (P = 0.002) and more pain (P = 0.015), in both genders, but not with dyspnoea. All regression analyses showed poorer physical outcomes below an SMI breakpoint of about 42-45 cm2 /m2 for men and 37-40 cm2 /m2 for women. In both genders, poor PF and more dyspnoea were significantly associated with low SMD.

Conclusions: Low muscle mass in NSCLC negatively affects the patients' PF, RF, and global QoL, possibly more so in men than in women. However, muscle mass must be below a threshold value before this effect can be detected.

Keywords: Body composition; Muscle mass; Non-small cell lung cancer; Quality of life.

© 2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.

Figures

Figure 1
Figure 1
The relation between the third lumbar (L3) skeletal muscle index (cm2/m2) and physical function, role function, and global quality of life (QoL).
Figure 2
Figure 2
The relation between the third lumbar (L3) skeletal muscle index (cm2/m2) and fatigue and dyspnoea.

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
    1. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non‐small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5:29–33.
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer. N Engl J Med 2002;346:92–98.
    1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non‐small cell lung cancer on progression‐free and overall survival: a meta‐analysis. J Natl Cancer Inst 2013;105:595–605.
    1. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105–1111.
    1. Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non‐small cell lung cancer. Drugs 2010;70:167–179.
    1. Fallowfield LJ, Harper P. Health‐related quality of life in patients undergoing drug therapy for advanced non‐small‐cell lung cancer. Lung Cancer 2005;48:365–377.
    1. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer 2007;15:39–46.
    1. Sanchez‐Lara K, Turcott JG, Juarez E, Guevara P, Nunez‐Valencia C, Onate‐Ocana LF, et al. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non‐small‐cell lung cancer: a prospective study. Nutr Cancer 2012;64:526–534.
    1. Scott HR, McMillan DC, Brown DJ, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non‐small cell lung cancer. Lung Cancer 2003;40:295–299.
    1. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 2013;21:3261–3270.
    1. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, et al. Cancer‐related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010;1:177–185.
    1. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non‐small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S–1137S.
    1. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:1539–1547.
    1. Arrieta O, De la Torre‐Vallejo M, López‐Macías D, Orta D, Turcott J, Macedo‐Pérez E‐O, et al. Nutritional Status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non‐small cell lung cancer. Oncologist 2015;20:967–974.
    1. Kazemi‐Bajestani SMR, Mazurak VC, Baracos V. Computed tomography‐defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 2015; Elsevier.
    1. Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo‐adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr 2016;35:724–730.
    1. Tan B, Brammer K, Randhawa N, Welch N, Parsons S, James E, et al. Sarcopenia is associated with toxicity in patients undergoing neo‐adjuvant chemotherapy for oesophago‐gastric cancer. Euro J Surg Oncol (EJSO) 2015;41:333–338.
    1. Jung H‐W, Kim JW, Kim J‐Y, Kim S‐W, Yang HK, Lee JW, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 2015;23:687–694.
    1. Sjøblom B, Grønberg BH, Benth JŠ, Baracos VE, Fløtten Ø, Hjermstad MJ, et al. Low muscle mass is associated with chemotherapy‐induced haematological toxicity in advanced non‐small cell lung cancer. Lung Cancer 2015;90:85–91.
    1. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol Ser A Biol Med Sci 2006;61:1059–1064.
    1. Fragala MS, Kenny AM, Kuchel GA. Muscle quality in aging: a multi‐dimensional approach to muscle functioning with applications for treatment. Sports Med 2015;45:641–658.
    1. Aubrey J, Esfandiari N, Baracos V, Buteau F, Frenette J, Putman C, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 2014;210:489–497.
    1. Antoun S, Lanoy E, Iacovelli R, Albiges‐Sauvin L, Loriot Y, Merad‐Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013;119:3377–3384.
    1. Sjøblom B, Grønberg BH, Wentzel‐Larsen T, Baracos VE, Hjermstad MJ, Aass N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non‐small cell lung cancer. Clin Nutr 2016;35:1386–1393.
    1. Helbekkmo N, Sundstrøm S, Aasebø U, Brunsvig PF, Von Plessen C, Hjelde H, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283–289.
    1. Grønberg BH, Bremnes RM, Fløtten Ø, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first‐line chemotherapy in advanced non‐small‐cell lung cancer. J Clin Oncol 2009;27:3217–3224.
    1. Fløtten Ø, Grønberg B, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first‐line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer 2012;107:442–447.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
    1. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ‐LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ‐C30) for use in lung cancer clinical trials. EORTC Study Group on quality of life. Eur J Cancer 1994;30A:635–642.
    1. Fayers PM, Aaronson NK, Bjordal K, Grønvold M, Curran D, Bottomley A. EORTC QLQ‐C30 Scoring Manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
    1. Cella D, Hahn EA, Dineen K. Meaningful change in cancer‐specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002;11:207–221.
    1. Shen W, Punyanitya M, Wang Z, Gallagher D, St‐Onge M‐P, Albu J, et al. Visceral adipose tissue: relations between single‐slice areas and total volume. Am J Clin Nutr 2004;80:271–278.
    1. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population‐based study. Lancet Oncol 2008;9:629–635.
    1. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer Science & Business Media; 2013.
    1. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551–561.
    1. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 2012;7: e29330.
    1. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012;99:550–557.
    1. Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co‐morbidities aggravating heart failure (SICA‐HF). Eur Heart J 2013;34:512–519.
    1. Engelen MPKJ, Safar AM, Bartter T, Koeman F, Deutz NEP. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol 2015;26:1960–1966.
    1. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials. Lancet Oncol 2016;17:519–531.
    1. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment–a systematic review. Crit Rev Oncol Hematol 2013;88:573–593.
    1. Maiolo C, Mohamed E, Carbonelli M. Body composition and respiratory function. Acta Diabetol 2003;40:s32–s38.
    1. Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross‐sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809–813.
    1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799.
    1. Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ‐C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol 2014;53:958–965.
    1. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 2008;16:447–451.
    1. Baracos VE. Cancer‐associated cachexia and underlying biological mechanisms. Annu Rev Nutr 2006;26:435–461.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2015;6:315–316.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner